MSN Group (MSN), a leading generic pharmaceutical company, announced the launch of the most-affordable Favipiravir, marketed under the brand name ‘FAVILOW’.
The medicine will be costing ₹33 with a recommended dose of 200 mg and will be available in all pharmacies across the country.
For mild cases
MSN successfully developed the active pharmaceutical ingredient (API) and the formulation for FAVILOW through its in-house R&D team. The medicine can be used for the treatment of mild to moderate COVID-19 patients.
“We are glad to launch our product during the current tough times as COVID-19 cases in India are increasing like never before. We as a company always believe that quality medicine has to be accessible and available to everyone. We are confident that our product will nurture hope in patients as it is both effective and affordable at the same time,” said CMD Dr. MSN Reddy on Thursday.
DCGI approved
‘Favipiravir’ has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID in adults and children, hospitalised with severe symptoms of the disease. FAVILOW (Favipiravir) will be available in 200 mg tablets that can be purchased from all pharmacies with a prescription by a healthcare practitioner.
MSN had earlier launched Oseltamivir 75 mg capsules, another anti-viral medication under the brand name ‘OSELOW’, and will be launching FAVILOW 400 mg very soon in the market as part of the COVID treatment range, a press release said.
For details, contact 9100591030 or email to customercare@msnlabs.com.
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Faster pages
Move smoothly between articles as our pages load instantly.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Personalised recommendations
A select list of articles that match your interests and tastes.
Briefing
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
